Andrew Dodson
UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH)
United Kingdom
Submit your idea
You will be redirected to our submission process.
UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH)
United Kingdom
Institute of Biomedical Sciences
United Kingdom
School of Medicine, Cardiff University
United Kingdom
Division of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency
Republic of Korea
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
Department Biomarker Academy, Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
Department of Pathology, Tu Du Hospital
Vietnam
Department of Pathology, 108 Military Central Hospital
Vietnam
Bureau of Accreditation Vietnam, Center for Standardization and Quality Control in Medical Laboratory of Ho Chi Minh City (CSQL)
Vietnam
Birmingham Quality (Member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
United Kingdom
Department Biomarker Academy, Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH)
United Kingdom
Manuscripts can be submitted to this Special Issue via the main journal or any other participating journal.
Submit your idea
You will be redirected to our submission process.